{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:15:05Z","timestamp":1783606505338,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","award":["IMM-11-0077"],"award-info":[{"award-number":["IMM-11-0077"]}],"id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10620-024-08732-y","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:30:12Z","timestamp":1732728612000},"page":"333-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serological Markers as Predictors of Anti-TNF Response in Children with Crohn\u2019s Disease"],"prefix":"10.1007","volume":"70","author":[{"given":"Yaara","family":"Lisai-Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Focht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Orlanski-Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dotan","family":"Yogev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Lev-Tzion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Ledder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Assa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Manuel","family":"Navas-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Baldassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Otley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror S.","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Atia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"8732_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.crohns.2012.03.006","volume":"7","author":"A Assa","year":"2013","unstructured":"Assa A, Hartman C, Weiss B, Broide E, Rosenbach Y, Zevit N et al. Long-term outcome of tumor necrosis factor alpha antagonist\u2019s treatment in pediatric Crohn\u2019s disease. J Crohns Colitis. 2013;7:369\u2013376.","journal-title":"J Crohns Colitis."},{"key":"8732_CR2","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","volume":"389","author":"S Kugathasan","year":"2017","unstructured":"Kugathasan S, Denson LA, Walters TD, Kim MO, Marigorta UM, Schirmer M et al. Prediction of complicated disease course for children newly diagnosed with Crohn\u2019s disease: a multicentre inception cohort study. The Lancet. 2017;389:1710\u20131718.","journal-title":"The Lancet."},{"key":"8732_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad301","author":"O Atia","year":"2024","unstructured":"Atia O, Friss C, Focht G, Magen Rimon R, Ledderman N, Ben-Tov A et al. Durability of adalimumab and infliximab in children with Crohn\u2019s disease: a nationwide comparison from the epi-IIRN cohort. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izad301.","journal-title":"Inflamm Bowel Dis."},{"key":"8732_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ibd.20329","volume":"14","author":"L De Ridder","year":"2008","unstructured":"De Ridder L, Rings EHHM, Damen GM, Kneepkens CMF, Schweizer JJ, Kokke FTM et al. Infliximab dependency in pediatric Crohn\u2019s disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353\u2013358.","journal-title":"Inflamm Bowel Dis."},{"key":"8732_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/ecco-jcc\/jjz111","volume":"14","author":"A Levine","year":"2020","unstructured":"Levine A, Chanchlani N, Hussey S, Ziv-Baran T, Escher JC, Amil Dias J et al. Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn\u2019s disease: results from the porto group growth study. J Crohns Colitis. 2020;14:71\u201378.","journal-title":"J Crohns Colitis."},{"key":"8732_CR6","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1097\/MIB.0000000000000937","volume":"22","author":"F Rinawi","year":"2016","unstructured":"Rinawi F, Assa A, Hartman C, Mozer Glassberg Y, Friedler VN, Rosenbach Y et al. Incidence of bowel surgery and associated risk factors in pediatric-onset Crohn\u2019s disease. Inflamm Bowel Dis. 2016;22:2917\u20132923.","journal-title":"Inflamm Bowel Dis."},{"key":"8732_CR7","doi-asserted-by":"crossref","unstructured":"Russell \u00c3RK, Ip B, Aldhous MC, Macdougall M, Drummond HE, Arnott IDR, et al. Anti-saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease. 2009. Available from: http:\/\/journals.lww.com\/jpgn","DOI":"10.1097\/MPG.0b013e318183e112"},{"key":"8732_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/ibd.20892","volume":"15","author":"AM Schoepfer","year":"2009","unstructured":"Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B et al. Phenotypic associations of Crohn\u2019s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss cohort. Inflamm Bowel Dis. 2009;15:1358\u20131367.","journal-title":"Inflamm Bowel Dis."},{"key":"8732_CR9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/ibd.21854","volume":"18","author":"F Rieder","year":"2012","unstructured":"Rieder F, Hahn P, Finsterhoelzl L, Schleder S, Wolf A, Dirmeier A et al. Clinical utility of anti-glycan antibodies in pediatric Crohn\u2019s disease in comparison with an adult cohort. Inflamm Bowel Dis. 2012;18:1221\u20131231.","journal-title":"Inflamm Bowel Dis."},{"key":"8732_CR10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1002\/ibd.21661","volume":"17","author":"GR Lichtenstein","year":"2011","unstructured":"Lichtenstein GR, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn\u2019s disease behavior. Inflamm Bowel Dis. 2011;17:2488\u20132496.","journal-title":"Inflamm Bowel Dis."},{"key":"8732_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/00365521.2016.1259653","volume":"52","author":"C Olbj\u00f8rn","year":"2017","unstructured":"Olbj\u00f8rn C, Cvancarova Sm\u00e5stuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Perminow G. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol. 2017;52:414\u2013419.","journal-title":"Scand J Gastroenterol."},{"key":"8732_CR12","doi-asserted-by":"publisher","unstructured":"Desir B, Amre DK, Lu S-E, Ohman-Strickland P, Dubinsky M, Fisher R, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn\u2019s disease. 2004 https:\/\/doi.org\/10.1053\/S1542-3565(03)00321-5","DOI":"10.1053\/S1542-3565(03)00321-5"},{"key":"8732_CR13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","volume":"17","author":"IDR Arnott","year":"2003","unstructured":"Arnott IDR, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn\u2019s disease. Aliment Pharmacol Ther. 2003;17:1451\u20131457.","journal-title":"Aliment Pharmacol Ther."},{"key":"8732_CR14","doi-asserted-by":"crossref","unstructured":"Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn\u2019s disease. 2002.","DOI":"10.1111\/j.1572-0241.2002.05689.x"},{"key":"8732_CR15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjv156","volume":"9","author":"T Billiet","year":"2015","unstructured":"Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F et al. Matrix-based model predicts primary response to infliximab in Crohn\u2019s disease. J Crohns Colitis. 2015;9:1120\u20131126.","journal-title":"J Crohns Colitis."},{"key":"8732_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1572-0241.2007.01652.x","volume":"103","author":"M Papp","year":"2008","unstructured":"Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2\/CARD15 genotype in a Hungarian IBD cohort. American Journal of Gastroenterology. 2008;103:665\u2013681.","journal-title":"American Journal of Gastroenterology."},{"key":"8732_CR17","doi-asserted-by":"publisher","unstructured":"Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn\u2019s disease. Inflamm Bowel Dis. 2011. 17. https:\/\/doi.org\/10.1002\/ibd.21386","DOI":"10.1002\/ibd.21386"},{"key":"8732_CR18","doi-asserted-by":"publisher","unstructured":"Kong DH, Kim YK, Kim MR, Jang JH, Lee S. Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer. Int J Mol Sci. 2018; 19. https:\/\/doi.org\/10.3390\/ijms19041057","DOI":"10.3390\/ijms19041057"},{"key":"8732_CR19","doi-asserted-by":"publisher","unstructured":"Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid a (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004; 314. https:\/\/doi.org\/10.1016\/j.bbrc.2003.12.096","DOI":"10.1016\/j.bbrc.2003.12.096"},{"key":"8732_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2019.10.034","volume":"158","author":"G D\u2019Haens","year":"2020","unstructured":"D\u2019Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E et al. Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins. Gastroenterology. 2020;158:515-526.e10.","journal-title":"Gastroenterology."},{"key":"8732_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/970890","author":"C Alkim","year":"2015","unstructured":"Alkim C, Alkim H, Koksal AR, Boga S, Sen I. Angiogenesis in inflammatory bowel disease. Int J Inflam. 2015. https:\/\/doi.org\/10.1155\/2015\/970890.","journal-title":"Int J Inflam."},{"key":"8732_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/MIB.0000000000000991","volume":"23","author":"AJ Yarur","year":"2017","unstructured":"Yarur AJ, Quintero MA, Jain A, Czul F, Barkin JS, Abreu MT. Serum amyloid a as a surrogate marker for mucosal and histologic inflammation in patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2017;23:158\u2013164.","journal-title":"Inflamm Bowel Dis."},{"key":"8732_CR23","unstructured":"Sans M, Julia\u00b4 J, Pan\u00e9 J, Ardite E, Ignasi Elizalde J, Arce Y, et al. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis"},{"key":"8732_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1053\/j.gastro.2022.07.048","volume":"163","author":"G Focht","year":"2022","unstructured":"Focht G, Cytter-Kuint R, Greer MLC, Pratt LT, Castro DA, Church PC et al. Development, validation, and evaluation of the pediatric inflammatory Crohn\u2019s magnetic resonance enterography index from the ImageKids study. Gastroenterology. 2022;163:1306\u20131320.","journal-title":"Gastroenterology."},{"key":"8732_CR25","unstructured":"https:\/\/prometheuslabs.com\/disease-tests\/ibd-sgi-diagnostic\/ [Internet]"},{"key":"8732_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ibd.21649","volume":"18","author":"D Turner","year":"2012","unstructured":"Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M et al. Mathematical weighting of the pediatric Crohn\u2019s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012;18:55\u201362.","journal-title":"Inflamm Bowel Dis."},{"key":"8732_CR27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/aje\/kwh101","volume":"159","author":"MS Pepe","year":"2004","unstructured":"Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882\u2013890.","journal-title":"Am J Epidemiol."},{"key":"8732_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.dld.2017.12.010","volume":"50","author":"S Ishihara","year":"2018","unstructured":"Ishihara S, Tada Y, Kawashima K, Kataoka M, Sonoyama H, Yamashita N et al. Serum amyloid A level correlated with endoscopic findings in patients with Crohn\u2019s disease\u2014possible biomarker for evaluating mucosal healing. Digestive and Liver Disease. 2018;50:53\u2013558.","journal-title":"Digestive and Liver Disease."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08732-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T19:51:19Z","timestamp":1737748279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08732-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["8732"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08732-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing interest declaration: YLG \u2013 None GF \u2013 None EOM \u2013 None DY \u2013 None RLT \u2013 None OL \u2013 None AA \u2013 None VMNL \u2013 None RNB \u2013 None AO \u2013 None DS \u2013 None AMG \u2013 None DT \u2013 For the past three years, has received consultation fees, research grants, royalties, or honorariaum from Janssen, Pfizer, Hospital for Sick Children (Canada), Ferring, AbbVie, Takeda, Atlantic Health System, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS OA \u2013 none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the local ethics committee of the participating medical centers and all participants signed informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}